These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 37138160)

  • 21. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.
    Ho CY; Troncoso JC; Knox D; Stark W; Eberhart CG
    Brain Pathol; 2014 Jan; 24(1):25-32. PubMed ID: 23714377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.
    Poggiolini I; Erskine D; Vaikath NN; Ponraj J; Mansour S; Morris CM; El-Agnaf OMA
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34072869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE
    Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. α-Synuclein Conformations in Plasma Distinguish Parkinson's Disease from Dementia with Lewy Bodies.
    Kannarkat GT; Zack R; Skrinak RT; Morley JF; Davila-Rivera R; Arezoumandan S; Dorfmann K; Luk K; Wolk DA; Weintraub D; Tropea TF; Lee EB; Xie SX; Chandrasekaran G; Lee VM; Irwin D; Akhtar RS; Chen-Plotkin AS
    bioRxiv; 2024 May; ():. PubMed ID: 38765963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy.
    Lin S; Leitão ADG; Fang S; Gu Y; Barber S; Gilliard-Telefoni R; Castro A; Sung K; Shen R; Florio JB; Mante ML; Ding J; Spencer B; Masliah E; Rissman RA; Wu C
    Neurobiol Dis; 2023 Mar; 178():106010. PubMed ID: 36702318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia.
    Chiu PY; Yang FC; Chiu MJ; Lin WC; Lu CH; Yang SY
    Sci Rep; 2022 Oct; 12(1):17919. PubMed ID: 36289355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo and autopsy validation of alpha-synuclein seeding activity using RT-QuIC assay in the gastrointestinal tract of patients with Parkinson's disease.
    Shin C; Han JY; Kim SI; Park SH; Yang HK; Lee HJ; Kong SH; Suh YS; Kim HJ; Choi YP; Jeon B
    Parkinsonism Relat Disord; 2022 Oct; 103():23-28. PubMed ID: 36029607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.
    Ruf VC; Shi S; Schmidt F; Weckbecker D; Nübling GS; Ködel U; Mollenhauer B; Giese A
    FEBS Open Bio; 2020 May; 10(5):883-893. PubMed ID: 32190992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies.
    Poggiolini I; Gupta V; Lawton M; Lee S; El-Turabi A; Querejeta-Coma A; Trenkwalder C; Sixel-Döring F; Foubert-Samier A; Pavy-Le Traon A; Plazzi G; Biscarini F; Montplaisir J; Gagnon JF; Postuma RB; Antelmi E; Meissner WG; Mollenhauer B; Ben-Shlomo Y; Hu MT; Parkkinen L
    Brain; 2022 Apr; 145(2):584-595. PubMed ID: 34894214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.
    Walker L; McAleese KE; Thomas AJ; Johnson M; Martin-Ruiz C; Parker C; Colloby SJ; Jellinger K; Attems J
    Acta Neuropathol; 2015 May; 129(5):729-48. PubMed ID: 25758940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.
    Kalia LV
    Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.
    Iranzo A; Fairfoul G; Ayudhaya ACN; Serradell M; Gelpi E; Vilaseca I; Sanchez-Valle R; Gaig C; Santamaria J; Tolosa E; Riha RL; Green AJE
    Lancet Neurol; 2021 Mar; 20(3):203-212. PubMed ID: 33609478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Misfolded α-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes.
    Vasilevskaya A; Martinez-Valbuena I; Anastassiadis C; Taghdiri F; Khodadadi M; Tarazi A; Green R; Colella B; Wennberg R; Mikulis D; Davis KD; Kovacs GG; Tator C; Tartaglia MC
    Mov Disord; 2023 Nov; 38(11):2125-2131. PubMed ID: 37792643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.